Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Retapamulin, 1% · 1 trial · 1 indication
"Clinical Success" at follow-up was defined as "Resolution of clinically meaningful signs and symptoms of infection recorded at baseline including a pus/exudate Skin Infection Rating Scale (SIRS) score of "0". Clinical response at follow-up was classified as "Clinical Failure" for all other cases. The SIRS consists of seven items (pus/exudates, crusting, erythema/inflammation, tissue warmth, tissue edema, itching and pain). Each item has a score ranging from 0 to 6 (0=absent, 6=severe). The SIRS total score was calculated as the sum of the scores of all 7 SIRS items.
| Arm | Type | Description |
|---|---|---|
| Retapamulin Ointment, 1% | EXPERIMENTAL | - |
| Placebo Ointment | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Retapamulin Ointment, 1% | DRUG | Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps. |
| Placebo ointment | DRUG | Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps. |
Inclusion criteria: * subject is aged 2 months or older * subject has secondarily-infected traumatic lesion (laceration, sutured wound or abrasion) * negative urine pregnancy test * subject has total skin infection rating scale score of at least 8, including pus/exudate score of at least 3 * subjec...
Retapamulin, 1% is a small molecule antibiotic used for bacterial skin infections and other bacterial infections. It is being developed by GSK plc (ticker: GSK) and is currently in Phase 3 clinical development for these indications.
Retapamulin, 1% is an antibiotic that works by inhibiting bacterial protein synthesis. It is being studied for the treatment of bacterial skin infections and other bacterial infections, including those caused by Staphylococcus aureus.
Retapamulin, 1% is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 3 clinical trials for bacterial skin infections.
Retapamulin, 1% is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy for bacterial skin infections.
Retapamulin, 1% has been studied in clinical trials including NCT00539994, a Phase 2 study in healthy adults nasally colonized with Staphylococcus aureus, and NCT00684177, a Phase 3 study in patients with secondarily-infected traumatic lesions. Both trials have been completed.
Retapamulin, 1% is also known by the brand name Altabax. It is an antibiotic ointment used to treat bacterial skin infections. The drug is being developed by GSK plc and is currently in Phase 3 clinical trials.